PACB · XBRL financial data

Pacific Biosciences of California financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PACB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of revenue	46	72	79	148	117	114
Cost of goods and services sold	46	—	—	—	—	—
Gross profit	33	59	49	53	37	46
Research and development	64	113	193	187	135	97
Selling, general and administrative	73	124	161	170	175	141
Total operating expenses	137	269	356	387	512	600
Operating income (loss)	(104)	(210)	(307)	(334)	(474)	(554)
Interest expense	0	13	15	14	13	7
Other income (expense)	2	0	8	33	24	15
Income tax expense (benefit)	—	(94)	0	(11)	0	0
Net income (loss)	29	(181)	(314)	(307)	(310)	(546)
Earnings per share, basic USD per share	0.18	(0.89)	(1.40)	(1.21)	(1.13)	(1.82)
Earnings per share, diluted USD per share	0.17	(0.89)	(1.40)	(1.21)	(1.59)	(1.82)
Weighted average shares, basic millions of shares	165	204	225	254	274	300
Weighted average shares, diluted millions of shares	175	204	225	254	288	300

Fiscal years (PACB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	82	461	325	180	55	64
Short-term investments	237	584	447	452	335	216
Marketable securities	255	595	565	465	—	—
Marketable securities, non-current	21	122	70	96	—	—
Accounts receivable	17	24	19	37	28	35
Inventory	14	25	50	57	59	49
Prepaid and other current assets	5	7	10	17	19	11
Total current assets	356	1,101	852	742	496	375
Property and equipment, net	25	33	42	36	31	24
Right-of-use asset	30	47	40	33	16	42
Goodwill	—	410	410	462	318	318
Total assets	414	2,007	1,767	1,746	1,260	784
Accounts payable	4	11	12	15	17	21
Accrued liabilities	17	36	33	46	23	34
Total current liabilities	39	72	263	95	66	73
Lease liability, non-current	38	50	41	32	15	57
Total liabilities	78	1,216	1,204	1,045	754	779
Accumulated deficit	(1,037)	(1,218)	(1,532)	(1,839)	(2,149)	(2,695)
Total stockholders' equity	335	791	563	701	507	5
Total liabilities and equity	414	2,007	1,767	1,746	1,260	784
Common shares outstanding (cover page) millions of shares	193	221	247	268	298	302

Fiscal years (PACB's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	29	(181)	(314)	(307)	(310)	(546)
Stock-based compensation	18	73	79	72	71	42
Net cash from operating activities	20	(111)	(263)	(259)	(206)	(111)
Purchases of property and equipment	1	6	17	9	6	3
Net cash from investing activities	(219)	(679)	116	5	124	115
Proceeds from issuing common stock	46	32	11	15	0	0
Net cash from financing activities	252	1,170	10	109	(43)	3
Net change in cash	—	380	(138)	(146)	(125)	8

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Pacific Biosciences of California	61	39	(36)*	310.8M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Senseonics Holdings	45	14	(30)*	52.9M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Mesa Laboratories	31	60	15	5.6M	—	Q1 FY27 10-QJun 30, 2026
Cytek Biosciences	74	48	1.4*	130.0M	—	Q2 FY26 10-QJun 30, 2026
Alamar Biosciences	122	34	not reported	69.5M	—	Q3 FY26 10-QSep 30, 2026
Crawford United	1.9	not reported	5.7*	not reported	—	Q3 FY25 10-QSep 30, 2025
Quantum-Si	24	0.3	(18)*	not reported	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Allient	42	154	14*	17.0M	—	Q2 FY26 10-QJun 30, 2026
Frequency Electronics	61	23	2.6	11.3M	—	Q1 FY27 10-QJul 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.